Biotech Business - August 6, 2024
CHMP has adopted a negative opinion on BioArctic’s lecanemab for the EU
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has communicated that it has adopted a negative opinion on BioArctic AB’s partner Eisai’s Marketing Authorization Approval (MAA) for lecanemab as treatment for Alzheimer’s disease. Lecanemab is already approved in the United States, Japan, China, South Korea, Hong Kong, and […]
Agreement - July 1, 2024
SciBase partner with a large health care group in Los Angeles
SciBase Holding continues to expand in California with a collaboration agreement with Unified Health. Unified Health has nine clinics in Southern California. “At Unified Health, we believe in providing our patients with exceptional medical care and access to the most advance medical technology. Our experienced team of providers are committed to delivering the highest quality […]
Agreement - May 10, 2024
Xbrane and STADA partner with Valorum Biologics
Xbrane Biopharma and STADA have entered into an exclusive licensing agreement with US biosimilars specialist Valorum Biologics for their ranibizumab biosimilar candidate. Valorum will pay a license fee of up to USD 45 million, plus royalties on net product sales. This fee, plus royalties paid by Valorum on net sales of the product, will be […]
New Market - April 24, 2024
AstraZeneca’s Voydeya approved in the EU as add-on treatment
Voydeya has been approved as an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have residual haemolytic anaemia. Voydeya is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of-care Ultomiris (ravulizumab) or Soliris (eculizumab) to address the needs of the approximately 10-20% of […]
Agreement - April 3, 2024
Oncopeptides collaborates with Vector Pharma FZCO
The two companies have announced a collaboration to commercialize Oncopeptides’ drug Pepaxti in the Middle East and North Africa countries of Saudi Arabia, Qatar, UAE, Bahrain, Kuwait, Oman, Algeria, Tunisia, Morocco, Libya, Lebanon, and Iraq. Under the terms of this exclusive agreement, Vector will distribute Pepaxti to patients in the MENA region for the treatment […]
New Market - March 4, 2024
Vicore enters license agreement with Nippon Shinyaku
Vicore Pharma has entered into an exclusive licensing agreement with Nippon Shinyaku to develop and commercialize Vicore’s drug candidate C21 in Japan. Under the terms of the agreement, Vicore will receive an upfront payment of USD 10 million and is entitled to potential development and commercial milestone payments up to a total of USD 275 […]
